Use of serine in preparing medicine for preventing and / or treating acute pancreatitis

Serine is used in the treatment of acute pancreatitis. By reducing inflammatory and oxidative stress responses, it significantly improves the prevention and treatment effects of pancreatitis, fills the gap in existing treatment methods, and provides new prospects for amino acid therapy.

CN115702892BActive Publication Date: 2024-11-08WEST CHINA HOSPITAL SICHUAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110925768.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-08-12
Publication Date
2024-11-08
Estimated Expiration
2041-08-12

AI Technical Summary

Technical Problem

The treatment of acute pancreatitis lacks specific drugs, and the effects of existing amino acid treatment methods vary greatly, and serine has not yet been used in this field.

Method used

Serine, as an amino acid, is used to prevent and treat acute pancreatitis by intraperitoneal injection or other forms. It has the effect of protecting pancreatic cells, reducing inflammation and oxidative stress responses, and is prepared as a pharmaceutical preparation to improve therapeutic effect.

Benefits of technology

Serine significantly reduces the pathological score, inflammatory response and cell damage of pancreatitis, improves the prevention and treatment effect of acute pancreatitis, and provides a safe and effective amino acid supplement treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115702892B_ABST
    Figure CN115702892B_ABST
Patent Text Reader

Abstract

The present invention provides the use of serine in preparing a drug for preventing and / or treating acute pancreatitis, and belongs to the technical field of pharmaceutical chemistry. Specifically provided is the use of a compound shown in formula I, or a salt thereof, or a stereoisomer thereof, or a solvate thereof, or a hydrate thereof in preparing a drug for preventing and / or treating pancreatitis, wherein R is selected from hydrogen and C1-C8 alkyl. Serine can effectively protect pancreatic acinar cells and has a good preventive and therapeutic effect on acute pancreatitis. Serine can be used to prepare a drug for preventing and / or treating acute pancreatitis, and has good application prospects. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of pharmaceutical chemistry, and specifically relates to use of serine in preparing a medicine for preventing and / or treating acute pancreatitis. Background Art

[0002] Acute pancreatitis (AP) is a common acute digestive disease, mainly caused by biliary tract diseases, alcohol consumption and hypertriglyceridemia. The course of AP is complex and changeable. Most AP patients are self-limited, and about 20% of patients may develop into severe cases, with local inflammation mediated by acinar cell damage developing into systemic inflammatory response syndrome, and finally persistent organ failure, with a mortality rate as high as 19-52%. At present, there is still a lack of sufficient understanding of the pathological mechanisms of AP and its severity, mainly including premature activation of trypsinogen, intracellular calcium overload, endoplasmic reticulum stress, inflammatory cascade reaction, etc. revealed by AP animal or cell models. Clinical treatment involves multidisciplinary comprehensive treatment such as fluid resuscitation, pain control, nutritional support, organ support and surgical intervention. There is a lack of specific therapeutic drugs, and the socioeconomic burden is heavy.

[0003] The acinar cells of the pancreas are mainly used to synthesize and secrete trypsinogen, pancreatic amylase, and pancreatic lipase. After AP occurs, the disorder of digestive function changes the homeostasis of protein, sugar, and lipid, and further metabolic changes occur as the disease progresses. If it develops into systemic inflammatory response syndrome, the body may be in a highly decomposable state, eventually leading to metabolic imbalance. The current review analysis shows that amino acid metabolism is significantly affected after AP occurs.

[0004] Amino acids, as AP modeling toxins and nutritional supplements, have always attracted much attention in AP research. The effects of amino acids on AP vary greatly. Intraperitoneal injection of high-dose basic amino acids (L-arginine, L-ornithine) into rodents causes mitochondrial damage and endoplasmic reticulum stress, resulting in a necrotic AP model; feeding young female mice with choline-deficient ethionine can lead to severe pancreatic necrosis. Glutamine, as an important nutritional support component, can improve the nutritional status of patients with severe AP, reduce mortality and complications; preventive administration of glycine, glutamate, etc. can effectively improve the pathology of AP experimental models and reduce inflammation levels. It can be seen that different amino acids have different effects on AP.

[0005] Currently, the effect of serine as a drug on AP has not been studied. Summary of the invention

[0006] The present invention provides the use of serine in the preparation of a drug for preventing and / or treating acute pancreatitis. The present invention finds that serine can improve local and systemic symptoms of AP. The present invention provides a safe and effective amino acid supplementation treatment plan and application prospects for clinical drug treatment and nutritional support, has very important application value in the treatment of AP, fills the gap in the current lack of nutritional treatment for AP from a metabolic perspective, and opens up the market prospects for new amino acid therapies.

[0007] The present invention provides the use of a compound represented by formula I, or a salt thereof, or a stereoisomer thereof, or a solvate thereof, or a hydrate thereof in the preparation of a medicament for preventing and / or treating pancreatitis:

[0008]

[0009] Wherein, R is selected from hydrogen and C1-C8 alkyl.

[0010] Furthermore, the compound is represented by formula II:

[0011]

[0012] Wherein, R is selected from hydrogen and C1-C8 alkyl.

[0013] Furthermore, the compound is serine, and its structure is as follows:

[0014]

[0015] Furthermore, the compound is L-serine, and its structure is as follows:

[0016]

[0017] Furthermore, the pancreatitis is acute pancreatitis.

[0018] Furthermore, the drug is a drug for protecting pancreatic cells.

[0019] Furthermore, the pancreatic cells are acinar cells.

[0020] Furthermore, the drug is a drug that reduces oxidative stress, endoplasmic reticulum stress and / or inflammatory response mechanisms.

[0021] Furthermore, the drug is a drug that reduces amylase activity, reduces lipase activity, inhibits trypsin activity, inhibits MPO content, reduces endoplasmic reticulum stress and apoptosis, inhibits IL-1β gene expression, inhibits Caspase-1 gene expression, and / or increases GPx and SOD content.

[0022] Furthermore, the drug is a preparation prepared with the aforementioned compound, or its salt, or its stereoisomer, or its solvate, or its hydrate as the main active substance, and pharmaceutically acceptable excipients or auxiliary ingredients.

[0023] Furthermore, the preparation is an injection, a tablet, a capsule, a powder, a solution, a parenteral nutritional supplement, an enteral nutritional supplement, a sustained-release preparation, or a controlled-release preparation.

[0024] Furthermore, the content of the aforementioned compound, or its salt, or its stereoisomer, or its solvate, or its hydrate in the unit preparation is 0.1 to 40 g.

[0025] The present invention also provides a medicine, which is a preparation prepared with the aforementioned compound, or its salt, or its stereoisomer, or its solvate, or its hydrate as the main active substance, and pharmaceutically acceptable excipients or auxiliary ingredients.

[0026] Furthermore, the preparation is an injection, tablet, capsule, powder, solution, parenteral nutrition supplement, enteral nutrition supplement, sustained-release preparation, controlled-release preparation;

[0027] Preferably, the content of the aforementioned compound, or its salt, or its stereoisomer, or its solvate, or its hydrate in the unit preparation is 0.1 to 40 g.

[0028] Serine can effectively protect pancreatic cells, especially pancreatic acinar cells, and has a good preventive and therapeutic effect on acute pancreatitis. Serine can be used to prepare drugs for preventing and / or treating acute pancreatitis, and has good application prospects.

[0029] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.

[0030] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1The results of the study on the protective effect of serine on AP induced by caerulein: A is a schematic diagram of caerulein modeling, serine administration and sampling time; B is the result of reducing pancreatic tissue pathological damage at a serine dose of 4.8 g / kg at 12 h; C is the pancreatic edema, inflammation, necrosis and total score of each group at 12 h; D is the serum pancreatic amylase activity of each group at 12 h; E is the serum pancreatic lipase activity of each group at 12 h; F is the trypsin activity of each group at 12 h; G is the pancreatic myeloperoxidase (MPO) activity of each group at 12 h; H is the serum glutathione peroxidase (GPx) activity of each group at 12 h; I is the serum superoxide dismutase (SOD) activity of each group at 12 h; J is the eukaryotic initiation factor 2 of the endoplasmic reticulum stress pathway in each group at 8 h and 12 h The relative expression levels of genes in the inflammatory signaling pathways IL-1β, Caspase-1 and ReLA were analyzed. Figure 1 In CI, gray (left) is the blank control group (Ctrl), red (middle) is the model group (CER-AP 12h), and blue (right) is the drug-treated group (CER-AP 12h+S). Figure 1 The left side of each time point in J is the blank control group, the middle is the model group, and the right side is the drug-treated group. P < 0.05 between groups was considered to be a significant difference.

[0032] Figure 2The protective effect of serine on L-arginine-induced acute pancreatitis: A is a schematic diagram of L-arginine modeling, serine administration and sampling time; B is the result of reducing pancreatic tissue pathological damage at a serine dose of 4.8 g / kg at 72 h; C is the total score of pancreatic edema, inflammation and necrosis in each group at 72 h; D is the serum pancreatic amylase activity in each group at 72 h; E is the pancreatic lipase activity in each group at 72 h; F is the trypsin activity in each group at 72 h; G is the pancreatic MPO activity in each group at 72 h; H is the relative expression levels of pancreatic endoplasmic reticulum stress pathway molecular chaperone binding immunoglobulin protein (BIP) (i), protein kinase RNA-like endoplasmic reticulum kinase (PERK) (ii), eIF2α (iii), CHOP (iv) and ATF4 (v) genes in each group at 72 h; I is the relative expression levels of inflammatory RelA (i), Caspase 1(ii), IL-1β(iii) and apoptosis signaling pathway cysteine ​​protease-12 (Caspase12)(iv) gene relative expression levels; J is the relative expression levels of CHOP and Caspase 1 protein. Figure 2 In CI, the gray (left) is the blank control group (Ctrl), the red (middle) is the model group (L-Arg-AP 72h), and the blue (right) is the drug-treated group (L-Arg-AP 72h+S). P<0.05 between the groups was considered significant.

[0033] Figure 3The protective effect of serine on acinar cell necrosis: A is the staining results of Hoechest33342 and PI, where Ctrl is the blank control group, taurolithocholate-3-sulfate (TLCS) is the model group, and TLCS+S is the 100mM serine treatment group; B is the ATP generation result, from left to right are blank control group, blank treated with 100mM serine group, TLCS stimulated for 15min model group, TLCS stimulated for 15min and treated with 100mM, TLCS stimulated for 30min model group, TLCS stimulated for 30min and treated with 100mM serine; C is the calcium overload test result, where Ctrl is the blank control group, Ser (100mM) is the group treated with serine without modeling , CCK (100nM) was the model group, and CCK+Ser was the serine administration group; D was the ROS generation detection result of the acinar cells stimulated by TLCS and treated with 100mM serine; E was the ROS generation detection result of the acinar cells stimulated by H2O2 and treated with 100mM serine; F was the ROS generation detection result of the acinar cells stimulated by L-arginine and treated with 100mM serine; G was the detection result of 100mM serine reducing the gene expression of xanthine oxidoreductase (XOR) (i), reducing the gene expression of endoplasmic reticulum stress signaling pathway BIP, eIF2α and CHOP (ii-iv); reducing the expression of apoptosis-related gene Caspase-12 and inflammatory Caspase-1 (v-vi). Figure 3 In G, the gray (left) is the blank control group, the red (middle) is the model group, and the blue (right) is the drug-treated group. P < 0.05 between the groups was considered to be a significant difference. DETAILED DESCRIPTION

[0034] The raw materials and equipment used in the specific embodiments of the present invention are all known products and are obtained by purchasing commercially available products.

[0035] The structure of the raw material serine is as follows:

[0036]

[0037] Example 1: Study on the protective effect of serine on caerulein-induced acute pancreatitis

[0038] 1. Experimental methods

[0039] (1) Establishment of AP model induced by cerulein: Male C57BL / 6 mice (20-25 g) were randomly divided into groups. 10 μg / mL cerulein was prepared with PBS and stored in aliquots at -80°C. Mice in the model group were intraperitoneally injected with 50 μg / kg cerulein for 7 consecutive times, with an interval of 1 h between each injection. The end time of the first injection was recorded as 0 h. The blank control group was injected with the same dose of solvent.

[0040] (2) Animal grouping and treatment: 35 male C57BL / 6 mice were randomly divided into 5 groups (N=7), blank control group, model group (divided into 2 groups according to the sampling time point, 8h group and 12h group) and drug administration group (divided into 2 groups according to the sampling time point, 8h group and 12h group). Drug administration was performed at 0h, 4h, and 8h after the first injection of caerulein. Serine in the drug administration group was dissolved in PBS and intraperitoneally injected into mice at 4.8g / kg; the blank control group and the model group were injected with the same dose of solvent.

[0041] (3) Sample collection and measurement:

[0042] Mice in each group were killed 8h and 12h after the first injection of caerulein, and blood, pancreas and other tissues were collected. The blood samples were kept at room temperature for 30min, centrifuged at 1500g and room temperature for 15min, and the supernatant was taken again at 1500g and centrifuged at room temperature for 7min. The supernatant was taken and stored at -80℃ for testing after aliquoting. The pancreatic tissue was divided into 4 parts: the head of the pancreas was used for pancreatic MPO determination; the pancreatic body was divided into two parts, 50mg for pathological detection and 50mg for protein expression determination; the tail of the pancreas was used for ribonucleic acid (RNA) extraction and real-time fluorescence quantitative polymerase chain reaction (RT-qPCR).

[0043] ① Determination of pathological and biochemical indicators: Pancreatic tissue pathological sections were prepared and H&E stained. The pancreatic pathological scoring standard was based on the reference 1 (Moreno C, Nicaise C, Gustot T, Quertinmont E, Nagy N, Parmentier M, Louis H, Deviere J. Chemokine receptor CCR5deficiency exacerbates cerulein-induced acute pancreatitis in mice. Am J Physiol Gastrointest Liver Physiol. 2006; 291(6): G1089-99.). The serum amylase and lipase activities were determined using Nanjing Jiancheng amylase and lipase kits, and the mouse IL-6 ELISA kit was used to detect serum IL-6.

[0044] ② Determination of MPO in pancreas: MPO was determined according to the method of reference 2 (Dawra R, Ku YS, Sharif R, Dhaulakhandi D, Phillips P, Dudeja V, Saluja AK. An improved method for extracting myeloperoxidase and determining its activity in the pancreas and lungs during pancreatitis. Pancreas; 2008; 37(1): 62-8.), and trypsin activity was determined by the substrate Boc-Gln-Ala-Arg-MCA hydrolysis method.

[0045] ③ Determination of gene and protein expression of inflammatory signaling pathways and endoplasmic reticulum stress: RNA was extracted from the pancreas in RNA Later by Trizol method, reverse transcribed into cDNA, and the genes of key metabolic enzymes were detected by fluorescence quantitative PCR (RT-qPCR). About 20 mg of pancreas was collected and ground with low-temperature liquid nitrogen, added to ice RIPA containing protease inhibitors and phosphatase inhibitors (10 mg / 100 μL), lysed on ice for 30 minutes, centrifuged at 12000g×10min, 4℃, and the supernatant protein was collected. The protein concentration was quantified by BCA method. The rest was added with 5× Loading buffer, denatured in a metal bath at 95℃ for 10min, and used for WB experiment to determine the changes in protein expression. The mouse pancreatic paraffin sections were used for immunohistochemistry (IHC) experiment to detect the protein expression of the above metabolic enzymes, that is, the paraffin sections were dewaxed, antigen repaired, blocked, incubated with primary and secondary antibodies respectively, developed with diaminobenzidine carbon tetrachloride substrate, counterstained with hematoxylin, and dehydrated and transparently sealed.

[0046] ④ Determination of SOD and GPx in serum: After the cells are fully lysed, centrifuge at 4000g×10min at 4°C to obtain the supernatant, and use the Nanjing Jiancheng kit to determine the enzyme activities of GPx and SOD in the cells.

[0047] 2. Experimental results

[0048] Depend on Figure 1 As shown in B and 1C, the pancreas of mice induced by caerulein showed severe edema, inflammatory infiltration and a certain degree of necrosis, while intraperitoneal injection of serine could alleviate various pathological scores to varying degrees. Figure 1 D and 1E show that the pancreatic amylase and lipase levels of mice with pancreatitis model after caerulein injection increased significantly, while serine can significantly reduce the activity of amylase and also has a decreasing trend for lipase. Trypsin activity is inhibited in normal pancreatic tissue. After trypsinogen is converted into pancreatic protein, it will damage the acinar cells. Figure 1 As can be seen from F, serine can inhibit trypsin activity. MPO is related to the neutrophil content in tissues. Figure 1 G shows that serine can significantly inhibit the content of MPO. GPx and SOD are indicators for evaluating the state of oxidative stress. Figure 1 It can be seen from H and 1I that serine can increase the content of GPx and SOD. eIF2α and Chop are important indicators related to the endoplasmic reticulum stress signaling pathway and apoptosis; Figure 1 In J, eIF2α and Chop showed that serine could significantly reduce endoplasmic reticulum stress and apoptosis in 12 hours. IL-1β, Caspase-1 and ReLA are all factors that reflect the inflammatory state. Figure 1It can be seen from the expression of IL-1β, Caspase-1 and ReLA in J that serine can significantly reduce the expression of these genes at 8 hours, and can significantly inhibit the gene expression of IL-1β and Caspase-1 at 12 hours.

[0049] Therefore, serine improves both systemic and local symptoms of the edema-type AP model induced by caerulein and can be used to prevent and / or treat acute pancreatitis.

[0050] Example 2: Study on the protective effect of serine on acute pancreatitis induced by L-arginine

[0051] 1. Experimental methods

[0052] (1) Establishment of L-arginine-induced AP model: Male C57BL / 6 mice (20-25 g) were randomly divided into groups. 8.8% L-arginine was prepared with physiological saline, pH 7.0. 4 g / kg L-arginine was injected twice in succession, with an interval of 1 h between each injection. The end of the first injection was recorded as 0 h. The blank control group was injected with the same dose of solvent.

[0053] (2) Animal grouping and treatment: 45 male C57BL / 6 mice were randomly divided into 3 groups (N=15), blank control group, model group and drug administration group. Drug administration was performed 4h, 8h, 24h, 28h, 32h, 48h, 52h, and 58h after the first injection of L-arginine. Serine in the drug administration group was dissolved in PBS and intraperitoneally injected into mice at 4.8g / kg; the blank control group and the model group were injected with the same dose of solvent.

[0054] (3) Sample collection and determination: The determination of pathological and biochemical indicators, and the determination of gene and protein expression of inflammatory signaling pathways and endoplasmic reticulum stress were the same as in Example 1, and the specific sampling time point was 72 hours after the first injection of arginine.

[0055] 2. Experimental results

[0056] Depend on Figure 2 As shown in B and 2C, the pancreas of mice developed severe edema, inflammatory infiltration and necrosis 72 hours after arginine modeling, while intraperitoneal injection of serine could alleviate the severity of the pathology to varying degrees. Figure 2 D and 2E show that after arginine injection, the pancreatic amylase and lipase of mice in the pancreatitis model increased significantly, while serine can significantly reduce the activity of amylase and also has a decreasing trend for lipase. Trypsin activity is inhibited in normal pancreatic tissue. After trypsinogen is converted into pancreatic protein, it will damage the acinar cells. Figure 2 As can be seen from F, serine can inhibit trypsin activity. MPO is related to the neutrophil content in tissues. Figure 2G shows that serine can significantly inhibit the content of MPO. Bip, PERK, eIF2α, CHOP and ATF4 are important indicators related to the endoplasmic reticulum stress signaling pathway and apoptosis; Figure 2 H(iv) shows that serine can significantly reduce endoplasmic reticulum stress and apoptosis at 72h. IL-1β, Caspase 1 and ReLA are all factors that reflect the inflammatory state. Figure 2 I(i-iv) shows that serine can significantly reduce the expression of these genes at 72h. Figure 2 J showed that serine could reduce the expression of related endoplasmic reticulum stress and inflammatory pathway proteins within 72 hours.

[0057] Therefore, serine improves both systemic and local symptoms of the L-arginine-induced necrotizing AP model and can be used to prevent and / or treat acute pancreatitis.

[0058] Example 3: Study on the protective effect of serine on acinar cell necrosis

[0059] 1. Experimental methods

[0060] (1) Isolation of primary acinar cells: Male C57BL / 6 mice were sacrificed and pancreatic tissue was obtained by laparotomy. After washing with HEPES, collagenase was injected along the main pancreatic duct until the pancreas was full. The pancreas was digested at 37°C for 17 min and then repeatedly blown three times until the pancreas was digested. The pancreas was sieved through a 70 μm cell sieve and centrifuged at 300 g for 2 min at 25°C. The supernatant was discarded and the cell pellet was resuspended in HEPES to obtain primary acinar cells.

[0061] (2) In vitro experimental grouping: generally divided into blank control group (freshly isolated primary cells without any modeling agent stimulation), model group (500μM, 250μM or 125μM TLCs, 100μM H2O2, 20mM arginine or 100nM CCK can be added to induce the cell model according to the experimental purpose), and 100mM serine administration group. The general order of drug addition is: serine incubation for 30min, then adding modeling agent to stimulate for a certain period of time, and then centrifugation to collect cells for subsequent detection.

[0062] (3) Cell necrosis assay: Acinar cells were stimulated with 500 μM TLCS for 30 min to establish a model. The degree of cell necrosis was detected by PI / Hoechst33342 double staining. Necrotic cells and total cells were fluorescently labeled, and 6-8 fields of view were photographed under an inverted microscope. The cell necrosis rate was calculated, and the optimal concentration of serine, 100 mM, was screened and used in subsequent experiments.

[0063] (4) ATP determination: Acinar cells were stimulated with 250 μM TLCS for 15 or 30 min to establish the model. ATP lysis solution was added to the cell pellet after treatment, and the cells were lysed on ice for 30 min. The cells were then placed in a 95°C metal bath for 2 min to fully release intracellular ATP. The lysate was collected after centrifugation at 12,000 g for 5 min at 4°C for ATP content determination. After the working solution was diluted with ATP diluent, 100 μL was taken to a 96-well black board and allowed to stand at room temperature for 3 min to consume background ATP. Subsequently, 20 μL of cell lysis solution supernatant or standard was added, and the luminescence value was immediately detected using a multifunctional microplate reader and standardized with the amount of cell protein.

[0064] (5) Ca 2+ Determination: Freshly isolated acinar cells, serine was added to the drug group, the blank control group and the 100nM CCK model group were added with the same volume of HEPES, and all groups were added with DMSO-dissolved Fluo-4 AM probe (2mM, final concentration 5μM) at the same time, and incubated together in the dark for 30min. 300g×2min, 25℃ centrifugation, discard the supernatant, and wash twice with HEPES. Add 500μL Hepes to resuspend the cells, and add 180μL of the cells to be tested to the 96-well black board. The fluorescence intensity of each well was detected by kinetic detection using a multifunctional microplate reader, with an excitation wavelength of 492-495nm and an emission wavelength of 517-527nm. The kinetic detection lasted for 300s, with a measurement interval of 0.3s. At 50s, 20μL HEPES or CCK was injected through a microinjection pump. The average of the first ten fluorescence values ​​of each group was taken as the initial fluorescence value F0, and the fluorescence value at each time point was F. The time-fluorescence curve was recorded with F / F0 as the ordinate and time as the abscissa to judge the intracellular Ca 2+ change.

[0065] (6) ROS determination: Freshly isolated acinar cells were stimulated with 125 μM TLCS, 100 μM H2O2 or 20 mM arginine to induce the model. The H2DCFDA probe was dissolved in DMSO and added to the acinar cells. The cells were loaded at 37°C in the dark for 30 min, centrifuged at 300 g for 5 min, and the supernatant was discarded. After the cells were resuspended in HEPES, they were divided into 96-well black plates. The fluorescence intensity of each well was detected by kinetic detection on a multifunctional microplate reader, with an excitation wavelength of 488 nm and an emission wavelength of 525 nm. The fluorescence values ​​of the baseline, after the addition of serine and the modeling agent were recorded, and the total monitoring time was 120 min. The initial fluorescence value of each group was recorded as F0, and the fluorescence value at each time point was F. The time-fluorescence curve was recorded with F / F0 as the ordinate and time as the abscissa to determine the changes in intracellular ROS.

[0066] (7) Determination of gene and protein expression of cellular inflammatory signaling pathways and endoplasmic reticulum stress: The model group used 500 μM TLCS to stimulate acinar cells, and the drug group used 100 mM serine. Fluorescence quantitative PCR (RT-qPCR) was used to detect changes in gene expression of key inflammatory pathways (NF-κB, IL-1β) and endoplasmic reticulum stress pathways (BIP, PERK, ATF4, CHOP).

[0067] 2. Experimental results

[0068] Depend on Figure 3 It can be seen that the use of TLCS to stimulate freshly isolated primary cells caused cell necrosis, which was stained with Hoechest33342 and PI respectively, and photographed under a fluorescence microscope. As shown in Figure (3A), serine can significantly reduce the uptake rate of PI in the model group, indicating that serine has a significant protective effect on the necrosis of acinar cells induced by TLCS. Cellular ATP is an important indicator for measuring cell energy production and mitochondrial function. It can be seen from Figure (3B) that at different times after TLCS stimulation of cells, serine can significantly maintain or even increase the generation of ATP. Calcium overload is an important mechanism of AP. CCK stimulation of cells will cause an increase in calcium flow in a short period of time, while serine can significantly reduce calcium flow (3C). TLCS (3D), H2O2 (3E), and arginine (3F) will cause an increase in ROS in acinar cells, while serine can reduce ROS. Endoplasmic reticulum stress is one of the early mechanism events of AP. It can be seen that serine not only reduces the gene expression of the redox-related enzyme XOR, but also reduces the gene expression of the endoplasmic reticulum stress signaling pathway and reduces the expression of apoptosis and inflammation-related genes Caspase-1 and 12 ( Figure 3 G).

[0069] The above experimental results indicate that serine has the effect of preventing or treating acute pancreatitis.

[0070] In summary, serine can effectively protect pancreatic cells, especially pancreatic acinar cells, and has a good preventive and therapeutic effect on acute pancreatitis. Serine can be used to prepare drugs for preventing and / or treating acute pancreatitis, and has good application prospects.

Claims

1. Use of a compound or a salt thereof as the sole active ingredient in the preparation of a medicament for preventing and / or treating pancreatitis, characterized in that: The compound is L-serine, and its structure is as follows: ; The pancreatitis is acute pancreatitis without diabetes.

2. The use according to claim 1, characterized in that: The drug is a preparation prepared with the compound or its salt as claimed in claim 1 as the only active substance and pharmaceutically acceptable excipients.

3. The use according to claim 2, characterized in that: The preparation is injection, tablet, capsule or powder.

4. The use according to claim 2, characterized in that: The preparation is a solution.

5. The use according to claim 2, characterized in that: The preparation is a parenteral nutritional supplement and an enteral nutritional supplement.

6. The use according to claim 2, characterized in that: The preparation is a sustained-release preparation or a controlled-release preparation.

7. The use according to claim 2, characterized in that: The content of the compound or its salt as claimed in claim 1 in the unit preparation is 0.1 to 40 g.